Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design
A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of...
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
Study Objective: Compare longitudinal HIV-1 antibody responses among HIV-1 infected participants that either did or did not...
This study is being done in people who are starting HIV treatment and who live in areas where the TB infection rate is high. The...
